.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Consequently, GSK recently announced its acquisition of 35Pharma to advance a promising GSK pulmonary hypertension drug candidate. This $950 million cash deal represents the second major move by new CEO Luke Miels. Specifically, the acquisition focuses on HS235, an experimental therapy designed to treat pulmonary hypertension. This condition currently affects over 80 million people globally and remains a life-shortening disease. Therefore, medical professionals closely watch these developments in the respiratory pipeline.
Furthermore, HS235 targets patients who suffer from obesity and a specific type of heart condition. Early studies on obese mice with preserved ejection fraction showed that the drug effectively reduced fat mass. Notably, it also boosted heart function during these preclinical trials. Additionally, researchers believe that if clinical trials succeed, patients might only require an injection every four weeks. This reduced dosing frequency could significantly improve patient compliance and quality of life.
Simultaneously, Miels aims to counter looming patent expiries for GSK's top-selling HIV medications. This deal follows a $2.2 billion acquisition of RAPT Therapeutics earlier this year. Moreover, GSK secured global rights to kidney disease therapies from Frontier Biotechnologies just this week. These strategic bolt-on deals reflect a broader shift toward specialized therapeutic areas. Consequently, the company avoids the increasingly crowded general obesity treatment market. Instead, GSK prioritizes the downstream effects of obesity, such as liver and heart diseases.
Q1: What is the primary target of the drug HS235?
HS235 targets pulmonary hypertension, specifically in patients with obesity and heart conditions like preserved ejection fraction.
Q2: How often would patients receive the HS235 injection if approved?
Clinical trials suggest the injectable drug could be administered once every four weeks or potentially even less frequently.
Q3: Why is GSK focusing on niche obesity-related diseases?
The company seeks to avoid the crowded general obesity market by focusing on downstream effects like liver, heart, and respiratory issues.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
GSK buys 35Pharma for $950M to acquire HS235, an experimental pulmonary hypertension drug targeting patients with heart conditions and obesity....
5 months ago
A landmark study analyzing over 56,000 adult health records in Delhi-NCR reveals that hypertension and diabetes coexistence affects nearly 5% of adults. The prevalence doubles expected rates and rises sharply after age 40. Early integrated screening is essential to prevent microvascular and macrovascular complications.
Today
An overview of surrogacy laws in India and global regulations, analyzing the transition to altruistic surrogacy, eligibility criteria, international cross-border challenges, and clinical compliance requirements for healthcare providers.
Today
A multicenter J-CASE survey study reveals that left ventricular apical longitudinal strain (LV-apical LS) independently predicts all-cause death in patients with immunoglobulin light-chain (AL) cardiac amyloidosis, establishing an optimal prognostic cut-off threshold of 15.9%.
Today
Researchers developed a Haversian-inspired composite scaffold that addresses delayed vascularization and wet-state mechanical deterioration in critical bone defect repair. By integrating spatially programmed calcium phosphate minerals and selective silica reinforcement, the design promotes vascularized bone repair.
Yesterday
A study of hospitalized adult patients with severe eating disorders revealed that while serum leptin increases linearly with weight gain during early refeeding, thyroid hormones show a biphasic trajectory. Low T3 and undetectable leptin frequently persist at discharge, highlighting delayed endocrine recovery.
Today
